GBI Research, a leading business intelligence provider, has released its latest research Women's Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market. The report provides in-depth analysis of the drivers and barriers that affect the global Women's Health market and analyzes the markets for women's health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenues and annual cost of therapy are forecast until 2017 for the key geographies, as well as for the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research finds that the women's health therapeutics market will grow rapidly, largely due to the introduction of new therapies and the increased awareness among patients and physicians in two of the largest segments within WH disorders, the menopause and osteoporosis. Novel non-hormonal therapeutics will become more popular during the forecast period. Though many of the major selling drugs in the osteoporosis market are set to lose patent protection in 2012, the launch of effective therapies such as Prolia (recently launched in 2010) will drive the market revenues.